Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...